Please assess the completion status of the following clinical trial:

Trial Title: Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Cohort A~  1. Patient has provided written informed consent.~* Cohort B~  1. Need for long-term oral anticoagulation;~ 2. Patient has provided written informed consent.~Exclusion Criteria:~* Cohort A~  1. Need for long-term oral anticoagulation;~ 2. Drug-eluting stent implantation within 3 months prior to TAVI procedure;~ 3. Bare-metal stent implantation within 1 month prior to TAVI procedure;~ 4. Allergy or intolerance to aspirin or clopidogrel.~* Cohort B~  1. Drug-eluting stent implantation within 3 months prior to TAVI procedure;~ 2. Bare-metal stent implantation within 1 month prior to TAVI procedure;~ 3. Allergy or intolerance to (N)OAC or clopidogrel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin + Clopicogrel (Cohort A) (Type: ACTIVE_COMPARATOR): Cohort A: patients will receive clopidogrel (75mg quaque die (qD), 3 months) on top of low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patient in Cohort A doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI.
- Aspirin monotherapy (Cohort A) (Type: ACTIVE_COMPARATOR): Cohort A: patients will receive low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patients doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
- OAC + Clopicogrel (Cohort B) (Type: ACTIVE_COMPARATOR): Cohort B: patients will receive clopidogrel (75mg qD, 3 months) on top of OAC (according to its indication). The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. aspirin) at least 5 days prior to the TAVI procedure.
- OAC monotherapy (Cohort B) (Type: ACTIVE_COMPARATOR): Cohort B: patients will receive OAC according to its indication. It is recommended to continue the OAC therapy peri-procedural (International Normalized Ratio aimed at 2.0). It is recommended to omit antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).